ReviewDrugs2021
Cannabis-Based Medicines and Medical Cannabis in the Treatment of Nociplastic Pain.
Review in Drugs, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 32 citations in OpenAlex.
- UK Medical Cannabis Registry: a case series analysing clinical outcomes of medicinal cannabis therapy for fibromyalgia.Clinical rheumatology · 2026Article
- Endocannabinoid system attenuates emotional stress-induced orofacial musculoskeletal pain in rats.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas · 2026Article
- The impact of tetrahydrocannabinol on central pain modulation in chronic pain: a randomized clinical comparative study of offset analgesia and conditioned pain modulation in fibromyalgia.Journal of cannabis research · 2025Article
- Looking beyond traditional pain outcomes to better evaluate cannabis's true potential and limitations in chronic pain management.Experimental and clinical psychopharmacology · 2025Review
- Fibromyalgia: do I tackle you with pharmacological treatments?Pain reports · 2025Review
- Nociplastic pain: controversy of the concept.The Korean journal of pain · 2025Review
- Nociplastic Pain: A Critical Paradigm for Multidisciplinary Recognition and Management.Journal of clinical medicine · 2024Article
- Adverse Ocular Impact and Emerging Therapeutic Potential of Cannabis and Cannabinoids: A Narrative Review.Clinical ophthalmology (Auckland, N.Z.) · 2024Review
- Cannabis therapy in rheumatological diseases: A systematic review.Northern clinics of Istanbul · 2024Review
- Drug Interactions of Tetrahydrocannabinol and Cannabidiol in Cannabinoid Drugs.Deutsches Arzteblatt international · 2023Review
- Review
- What Do We Know about Nociplastic Pain?Healthcare (Basel, Switzerland) · 2023Review
- The role of cannabis in treatment-resistant fibromyalgia women.Pain practice : the official journal of World Institute of Pain · 2023Article
- Review
- Modern Principles of Diagnosis and Treatment in Complex Regional Pain Syndrome.Deutsches Arzteblatt international · 2022Article
- Tetrahydrocannabinol and cannabidiol medicines for chronic pain and mental health conditions.Inflammopharmacology · 2022Review
- Reduced Endocannabinoid Tone in Saliva of Chronic Orofacial Pain Patients.Molecules (Basel, Switzerland) · 2022Article
- Review
- Long-lasting reflexive and nonreflexive pain responses in two mouse models of fibromyalgia-like condition.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nociplastic pain is defined as pain due to sensitization of the nervous system, without a sufficient underlying anatomical abnormality to explain the severity of pain. Nociplastic pain may be manifest in various organ systems, is often perceived as being more widespread rather than localized and is commonly associated with central nervous system symptoms of fatigue, difficulties with cognition and sleep, and other somatic symptoms; all features that contribute to considerable suffering. Exemplified by fibromyalgia, nociplastic conditions also include chronic visceral pain, chronic headaches and facial pain, and chronic musculoskeletal pain. It has been theorized that dysfunction of the endocannabinoid system may contribute to persistent pain in these conditions. As traditional treatments for chronic pain in general and nociplastic pain in particular are imperfect, there is a need to identify other treatment options. Cannabis-based medicines and medical cannabis (MC) may hold promise and have been actively promoted by the media and advocacy. The medical community must be knowledgeable of the current evidence in this regard to be able to competently advise patients. This review will briefly explain the understanding of nociplastic pain, examine the evidence for the effect of cannabinoids in these conditions, and provide simplified guidance for healthcare providers who may consider prescribing cannabinoids for these conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.